Jove
Visualize
Contact Us

Related Experiment Videos

Islet amyloid polypeptide and type 2 diabetes.

Lucy Marzban1, Kirily Park, C Bruce Verchere

  • 1British Columbia Institute for Children's and Women's Health, Department of Pathology and Laboratory Medicine, The University of British Columbia, 950 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4.

Experimental Gerontology
|April 3, 2003
PubMed
Summary

Type 2 diabetes involves beta-cell failure linked to islet amyloid deposits. Inhibiting islet amyloid formation may offer a therapeutic strategy for type 2 diabetes by protecting beta-cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regenerative macrophages enhance stem cell-derived β cell function and engraftment.

Science advances·2026
Same author

Human and mouse regenerative macrophages enhance beta cell survival, function, and proliferation.

Islets·2026
Same author

Islet amyloid disrupts MHC class II antigen presentation and delays autoimmune diabetes in NOD mice.

Diabetologia·2025
Same author

Insulin production is sustained during DNA damage-mediated senescence in adult human beta cells.

Diabetologia·2025
Same author

Assessment of protein synthesis rate enables metabolic profiling of resident-immune cells of the islets of Langerhans.

Frontiers in immunology·2025
Same author

α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion.

Science advances·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Endocrinology and Metabolism
  • Cell Biology
  • Diabetes Research

Background:

  • Type 2 diabetes is characterized by progressive beta-cell failure, leading to reduced insulin secretion and hyperglycemia.
  • Pancreatic islet amyloid deposits are increasingly correlated with beta-cell loss in type 2 diabetes.
  • Islet amyloid polypeptide (IAPP), or amylin, is a key component of these deposits and is co-secreted with insulin.

Purpose of the Study:

  • To explore the role of islet amyloid formation in beta-cell failure in type 2 diabetes.
  • To investigate potential mechanisms contributing to islet amyloidogenesis.
  • To evaluate the therapeutic potential of inhibiting islet amyloid fibril formation.

Main Methods:

  • Review of existing evidence on islet amyloid formation and its link to type 2 diabetes.

Related Experiment Videos

  • Analysis of factors influencing IAPP processing and aggregation.
  • Consideration of therapeutic strategies targeting islet amyloid.

    • Main Results:

    • Islet amyloid formation, involving toxic IAPP aggregates, is implicated in beta-cell dysfunction in type 2 diabetes.
    • Increased IAPP secretion alone is insufficient for amyloid formation; impaired processing of its precursor (proIAPP) is also implicated.
    • Islet amyloid fibrils are toxic to beta-cells, contributing to disease progression.

    Conclusions:

    • Islet amyloid formation plays a significant role in beta-cell failure in type 2 diabetes.
    • Therapeutic strategies aimed at inhibiting islet amyloid fibril formation could be a promising approach to prevent beta-cell loss and treat type 2 diabetes.